{"id":47207,"date":"2015-03-04T08:50:26","date_gmt":"2015-03-04T13:50:26","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=47207"},"modified":"2015-05-15T18:33:20","modified_gmt":"2015-05-15T22:33:20","slug":"fda-testosterone-therapy-may-pose-cardiovascular-risks","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2015\/03\/04\/fda-testosterone-therapy-may-pose-cardiovascular-risks\/","title":{"rendered":"FDA: Testosterone Therapy May Pose Cardiovascular Risks"},"content":{"rendered":"<div id=\"stcpDiv\">\n<p id=\"p-3\">Men who use testosterone products to treat low testosterone may be at increased risk for myocardial infarction, stroke, and death, the <a href=\"www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm436280.htm\">FDA cautioned on Tuesday<\/a>. The agency is requiring a label change to warn of these risks and to clarify the approved uses for such products.<\/p>\n<p id=\"p-4\">The action \u2014 which updates <a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm436259.htm\">a drug safety communication from January 2014<\/a> \u2014 is based on studies that demonstrated a potential link between testosterone therapy and cardiovascular risks, and on contributions from an FDA advisory panel.<\/p>\n<p id=\"p-5\">The FDA emphasized that testosterone products are approved only for treating low testosterone caused by medical conditions such as disorders of the brain, pituitary gland, and testicles. Benefits for age-related low testosterone haven&#8217;t been demonstrated.<\/p>\n<p>&#8211; See more at: http:\/\/www.jwatch.org\/fw109934\/2015\/03\/04\/fda-testosterone-therapy-may-pose-cardiovascular-risks#sthash.46ZoNISE.dpuf<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Men who use testosterone products to treat low testosterone may be at increased risk for myocardial infarction, stroke, and death, the FDA cautioned on Tuesday. The agency is requiring a label change to warn of these risks and to clarify the approved uses for such products. The action \u2014 which updates a drug safety communication [&hellip;]<\/p>\n","protected":false},"author":346,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47207","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/47207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/346"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=47207"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/47207\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=47207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=47207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=47207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}